Polycystic ovarian syndrome (PCOS) is an endocrine disorder that causes an increase in androgen hormone production in women. It affects 5 -10% of premenopausal women, and genetics play a large role in whether you have PCOS.
No one gene causes PCOS, but there are genetic variants in several hormonal pathways that increase the risk for it. Researchers estimate that PCOS is about 70% heritable.[ref] Understanding which genetic variants you carry may help you figure out the most effective way for you to manage your PCOS.
Members will see their genotype report below, plus additional solutions in the Lifehacks section. Join today.
Symptoms of PCOS
PCOS symptoms include irregular menstrual cycles, high androgen hormones, and cysts in the ovaries. Other hallmarks of PCOS include weight gain, insulin resistance, and elevated luteinizing hormone (LH) levels.[ref]
The excess of androgen hormones may cause facial or back hair as well as male pattern baldness. Skin problems include hormonal acne.
PCOS is a ‘syndrome’, meaning that not all symptoms have to be present to have PCOS.
Also, not everyone with PCOS has ovarian cysts — and not everyone with ovarian cysts has PCOS.[ref]
Let’s take a deep dive into what causes PCOS… and then look at your specific genetic susceptibility.
The three main physiological changes that we will look at include:
- hormone dysregulation
- insulin resistance and hyperinsulinemia
- circadian rhythm changes
Hormonal Dysregulation in PCOS:
Before diving into what goes wrong with PCOS, let’s first look at the hormonal processes that generally go on during a menstrual cycle.
The start of menstruation (your period) is considered the beginning of the menstrual cycle. Estrogen and progesterone levels are both low at this point.
Follicle-stimulating hormone (FSH) rises a bit, causing the development of the new follicle (containing an egg) in the ovary. The follicle produces estrogen, causing estrogen to rise over the next week.
Around day 12 – 14, ovulation occurs, releasing the egg. During ovulation, the pituitary gland releases luteinizing hormone (LH) and FSH at higher levels. This spike in LH and FSH hormone levels coincides with a fall in estrogen levels and an increase in progesterone. The follicle that has released the egg cell will form a corpus luteum, a hormone-secreting structure that produces high levels of progesterone.
What does your body need to make all these reproductive hormones? The molecular basis for these steroid hormones is cholesterol, which is converted into pregnenolone, which is the precursor for other hormones.
There are two ways that pregnenolone can be converted into other hormones. The enzyme CYP17A1 can eventually convert pregnenolone into DHEA. Alternatively, the enzyme 3B-HSD can convert pregnenolone into progesterone.
DHEA can then be converted into testosterone or other androgens — or it can convert to estrone and other estrogens.
Insulin resistance and androgen hormone production:
A number of different hormone pathways can be involved in PCOS. Androgen hormones in women usually convert to estrogen. Higher estrogen levels feedback to the pituitary gland, causing an increase in LH (luteinizing hormone) during ovulation.[ref]
Thus, when levels of androgen hormones are too high and not appropriately converted to estrogen, it interferes with ovulation or the release of the egg. It causes what looks like cysts in the ovaries when the immature egg follicles aren’t released.
Women with PCOS often have problems with insulin resistance and higher blood glucose levels.
Insulin increases the production of androgens in women. For this reason, women’s increased testosterone levels show associations with insulin resistance. The system works both ways – giving women testosterone can increase insulin resistance. These hormones are all interrelated. In the ovaries, insulin stimulates the production of testosterone.[ref][ref]
About 20 – 30% of women with PCOS have high DHEA levels. DHEA is a precursor for androgens and estrogens.[ref]
Circadian rhythm disruption as a cause of PCOS:
New research shows that circadian rhythm disruption may play a key role in causing PCOS.[ref]
Quick background: What is circadian rhythm?
Your circadian rhythm is the built-in 24-hour clock that drives many processes in the body. The first thing that pops to mind is your sleep/wake cycle, but your body’s circadian clock is far more than just sleep.
Over a 24-hour period, your body’s metabolic and cellular functions rise and fall. Some processes take place at night, and others during the day. For humans (and almost all animals), this 24-hour rhythm is synchronized by light.
Circadian rhythm disruption is tied to many chronic diseases, including obesity, heart disease, and dementia. Think about what jet lag feels like — your brain’s not working right, your stomach is not feeling right, and everything’s just out of sync.
Circadian disruption on a smaller scale happens each time you stay up later than usual in an area with bright lights. This shift is called social jet lag.
The body’s circadian clock is driving the rise and fall of some key proteins — and these oscillations are synchronized by light. Electric lighting has been around now for more than a century, but that is a drop in the bucket compared to the human and animal history of only having sunlight or firelight. Thus, it is easy to see how circadian rhythm disruption is a modern mismatch of lifestyle vs. innate biological function.
Back to PCOS:
Researchers have used animal models to show that circadian rhythm disruption can cause the same alterations to hormones as are seen in PCOS. For a couple of decades, it was known that altering circadian rhythm could alter insulin sensitivity and androgen production. But this new research lays out and produces the PCOS phenotype simply by altering circadian rhythm.
The researchers used changes in light to show that alterations to the circadian clock genes caused the downstream effects on the hormones involved in PCOS.[ref]
Pregnancy with PCOS:
Women with PCOS are more likely to have problems with ovulation, which is a common cause of infertility.
In-vitro fertilization (IVF) is a common solution for PCOS infertility.[ref] There are also medications that your doctor can prescribe that alter your hormones at the right time in your cycle.
Overall statistics are hard to come by regarding the percentage of women with PCOS and infertility. Larger population studies point to women with PCOS being more likely to have fewer children but having similar overall fertility rates when looking only at women with 1 – 2 children.[ref]
Is PCOS reversible with diet?
There are a lot of websites that claim to have a dietary solution for PCOS symptoms. Most focus on healthy foods, and some claim a ketogenic diet works.[article][article]
Other medical-based websites claim that all you can do is manage the symptoms of PCOS and that there is no cure.[article]
I’ll add specific recommendations in the Lifehacks section below that integrate genetics with some research-based suggestions for diet, supplements, and exercise.
One thing that is not clear is whether weight loss (through whatever type of diet) will cure PCOS. A ‘risk factor’ for PCOS is obesity, so your doctor may tell you to lose weight. With this in mind, research points to weight gain is caused by PCOS instead of obesity as a cause of PCOS. Chicken or the egg.[ref]
Insulin sensitivity, rather than fad diets, may be better for managing PCOS through nutrition.
Hashimoto’s and PCOS:
Researchers have found autoimmune thyroid diseases, such as Hashimoto’s thyroiditis, at much greater levels in women with PCOS. Thus, if you or your doctor suspects that you have a thyroid problem, it is recommended to also test for autoimmune thyroid antibodies.[ref]
Related article: Thyroid hormones and your genes
Genetics and PCOS:
Twin studies show that PCOS is about 70% hereditary, with the rest due to various environmental or dietary causes.
PCOS is considered an ‘evolutionary paradox’ since it is common (10% of the population), highly heritable, and also can cause infertility. Scientists want to know why the genetic variants involved in PCOS have continued to be passed on to a large part of the population – especially since evolutionary theory says that it should be weeded out. Some theories on this include that women with PCOS are more ‘metabolically thrifty’ and likely to live through a famine. Others theorize that women who only have a few children are better mothers and the children are more likely to survive.
Evolutionary theorizing aside, understanding which genetic variants you carry may help you to find the right solution for your PCOS symptoms.
PCOS Genotype Report
Not a member? Join here. Membership lets you see your data right in each article and also gives you access to the member’s only information in the Lifehacks sections.
LHCGR gene: luteinizing hormone receptor
Variants in the luteinizing hormone/choriogonadotropin receptor (LHCGR) gene are associated with an increased risk of PCOS and variations in the insulin response. The LHCGR is the receptor for both luteinizing hormone (LH), which triggers ovulation, and human chorionic gonadotropin (hCG), which maintains pregnancy.
Check your genetic data for rs13405728 (23andMe v4, v5; AncestryDNA)
- A/A: typical
- A/G: increased insulin levels in PCOS, but decreased overall risk of PCOS in Asian pops
- G/G: increased insulin levels in PCOS[ref], but decreased overall risk of PCOS in Asian pops.[ref]
Members: Your genotype for rs13405728 is —.
Check your genetic data for rs2293275 (23andMe v4, v5; AncestryDNA):
- T/T: increased risk (3 – 4-fold) of PCOS[ref][ref][ref]
- C/T: increased risk for PCOS
- C/C: typical risk of PCOS
Members: Your genotype for rs2293275 is —.
DENND1A gene: Androgen hormone synthesis
Too much DENND1A increases androgen hormone synthesis in the cells in the ovaries.
Check your genetic data for rs10818854 (23andMe v4, v5; AncestryDNA):
Members: Your genotype for rs10818854 is —.
FSHB gene: Follicle-stimulating hormone
The luteinizing hormone to follicle-stimulating hormone (LH:FSH) ratio is important in PCOS. Higher LH:FSH ratio can disrupt ovulation.
Check your genetic data for rs11031006 (23andMe v4, v5; AncestryDNA):
- A/A: increased LH levels[ref]
- A/G: increased LH levels
- G/G: typical LH levels
Members: Your genotype for rs11031006 is —.
FSHR gene: receptor for FSH
The FSHR gene codes for the follicle-stimulating hormone receptor.
Check your genetic data for rs6166 (23andMe v4, v5; AncestryDNA):
Members: Your genotype for rs6166 is —.
ADIPOQ gene: regulating insulin
Adiponectin (ADIPOQ) is created by fat cells and helps to regulate energy metabolism and insulin.
Check your genetic data for rs2241766 (23andMe v4, v5):
- T/T: (most common genotype) higher (1.9x) risk of PCOS[ref]
- G/T: lower risk of PCOS (compared to T/T)
- G/G: lower risk of PCOS
Members: Your genotype for rs2241766 is —.
Check your genetic data for rs1501299 (23andMe v4, v5; AncestryDNA):
- T/T: decreased risk of PCOS[ref]
- G/T: typical risk of PCOS
- G/G: typical risk of PCOS
Members: Your genotype for rs1501299 is —.
MTNR1B gene: melatonin, insulin resistance, and circadian rhythm
The melatonin receptor 1B is part of regulating your body’s circadian rhythm. Melatonin is essential in regulating insulin release at night and can play a significant role in fasting glucose levels.
Check your genetic data for rs10830963 (23andMe v4, v5; AncestryDNA):
- C/C: typical
- C/G: increased risk of higher insulin levels; PCOS
- G/G: increased risk of higher insulin levels; PCOS[ref][ref]
Members: Your genotype for rs10830963 is —.
TNF gene: encodes TNF alpha, an inflammatory cytokine
Check your genetic data for rs1799964 -1031T>C (23andMe v4, v5; AncestryDNA):
- C/C: (usually) higher TNF-alpha levels[ref][ref], increased risk of PCOS[ref]
- C/T: somewhat higher TNF-alpha levels, increased risk of PCOS
- T/T: typical – generally not at higher risk for inflammatory diseases
Members: Your genotype for rs1799964 is —.
Check your genetic data for rs4645843 (23andMe v4; AncestryDNA):
- T/T: increased risk of PCOS[ref]
- C/T: increased risk of PCOS
- C/C: typical risk
Members: Your genotype for rs4645843 is —.
The rest of this article outlines natural solutions explained in context for the genetic variants listed in the genotype report. It is for Genetic Lifehacks members only. Consider joining today to see the rest of this article.
An active subscription is required to access this content.
Join Here for full access to this article, genotype reports, and much more!
Already a member? Log in below.
Related Articles and Topics:
BPA: How Your Genes Influence BPA Detoxification
BPA, a chemical found in some plastics, has been linked to a variety of effects on people, including obesity, insulin resistance, and epigenetic effects on the fetus. It is everywhere in our food supply. In fact, a CDC report showed that 92% of people have BPA in their urine.
Circadian Rhythms: Genes at the Core of Our Internal Clocks
Circadian rhythms are the natural biological rhythms that shape our biology. Most people know about the master clock in our brain that keeps us on a wake-sleep cycle over 24 hours. This is driven by our master ‘clock’ genes.
Selenium and Your Genes
Selenium is a trace element found in certain foods. Learn how selenium is used in the body, why it is important, and how genetic variants can make someone more susceptible to problems with a selenium-deficient diet.
Metformin: Longevity research and genetics
A decades-old diabetes drug now holds promise for increasing healthspan. Research shows that metformin may reduce the risk of some of the diseases of aging, thus increasing the number of years someone is healthy.
Balen, Adam H., and Anthony J. Rutherford. “Managing Anovulatory Infertility and Polycystic Ovary Syndrome.” BMJ, vol. 335, no. 7621, Sept. 2007, pp. 663–66. www.bmj.com, https://doi.org/10.1136/bmj.39335.462303.80.
Capalbo, A., et al. “The 312N Variant of the Luteinizing Hormone/Choriogonadotropin Receptor Gene (LHCGR) Confers up to 2·7-Fold Increased Risk of Polycystic Ovary Syndrome in a Sardinian Population.” Clinical Endocrinology, vol. 77, no. 1, July 2012, pp. 113–19. PubMed, https://doi.org/10.1111/j.1365-2265.2012.04372.x.
Corbett, Stephen, and Laure Morin-Papunen. “The Polycystic Ovary Syndrome and Recent Human Evolution.” Molecular and Cellular Endocrinology, vol. 373, no. 1–2, July 2013, pp. 39–50. PubMed, https://doi.org/10.1016/j.mce.2013.01.001.
Corbould, A. “Effects of Androgens on Insulin Action in Women: Is Androgen Excess a Component of Female Metabolic Syndrome?” Diabetes/Metabolism Research and Reviews, vol. 24, no. 7, Oct. 2008, pp. 520–32. PubMed, https://doi.org/10.1002/dmrr.872.
Day, Felix R., et al. “Causal Mechanisms and Balancing Selection Inferred from Genetic Associations with Polycystic Ovary Syndrome.” Nature Communications, vol. 6, Sept. 2015, p. 8464. PubMed Central, https://doi.org/10.1038/ncomms9464.
De Sousa, Sunita M. C., and Robert J. Norman. “Metabolic Syndrome, Diet and Exercise.” Best Practice & Research. Clinical Obstetrics & Gynaecology, vol. 37, Nov. 2016, pp. 140–51. PubMed, https://doi.org/10.1016/j.bpobgyn.2016.01.006.
Fernandez, Renae C., et al. “Sleep Disturbances in Women with Polycystic Ovary Syndrome: Prevalence, Pathophysiology, Impact and Management Strategies.” Nature and Science of Sleep, vol. 10, 2018, pp. 45–64. PubMed, https://doi.org/10.2147/NSS.S127475.
Furat Rencber, Selenay, et al. “Effect of Resveratrol and Metformin on Ovarian Reserve and Ultrastructure in PCOS: An Experimental Study.” Journal of Ovarian Research, vol. 11, no. 1, June 2018, p. 55. PubMed, https://doi.org/10.1186/s13048-018-0427-7.
Gao, Jing, et al. “The Association of DENND1A Gene Polymorphisms and Polycystic Ovary Syndrome Risk: A Systematic Review and Meta-Analysis.” Archives of Gynecology and Obstetrics, vol. 294, no. 5, Nov. 2016, pp. 1073–80. PubMed, https://doi.org/10.1007/s00404-016-4159-x.
Ghowsi, Mahnaz, et al. “The Effect of Resveratrol on Oxidative Stress in the Liver and Serum of a Rat Model of Polycystic Ovary Syndrome: An Experimental Study.” International Journal of Reproductive Biomedicine, vol. 16, no. 3, Mar. 2018, pp. 149–58.
Goodarzi, Mark O., et al. “DHEA, DHEAS and PCOS.” The Journal of Steroid Biochemistry and Molecular Biology, vol. 145, Jan. 2015, pp. 213–25. ScienceDirect, https://doi.org/10.1016/j.jsbmb.2014.06.003.
Goodarzi, Mark O, et al. “Replication of Association of DENND1A and THADA Variants with Polycystic Ovary Syndrome in European Cohorts.” Journal of Medical Genetics, vol. 49, no. 2, Feb. 2012, pp. 90–95. PubMed Central, https://doi.org/10.1136/jmedgenet-2011-100427.
Gu, Bon-Hee, et al. “Genetic Variations of Follicle Stimulating Hormone Receptor Are Associated with Polycystic Ovary Syndrome.” International Journal of Molecular Medicine, vol. 26, no. 1, July 2010, pp. 107–12. www.spandidos-publications.com, https://doi.org/10.3892/ijmm_00000441.
Hossein Rashidi, Batool, et al. “The Association Between Bisphenol A and Polycystic Ovarian Syndrome: A Case-Control Study.” Acta Medica Iranica, vol. 55, no. 12, Dec. 2017, pp. 759–64.
“How to Reverse PCOS Naturally [Affects, Supplements & Keto Diet].” Ruled Me, 11 Sept. 2017, https://www.ruled.me/reverse-polycystic-ovary-syndrome-pcos-naturally/.
Ismail, Alaa M., et al. “Adding L-Carnitine to Clomiphene Resistant PCOS Women Improves the Quality of Ovulation and the Pregnancy Rate. A Randomized Clinical Trial.” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 180, Sept. 2014, pp. 148–52. PubMed, https://doi.org/10.1016/j.ejogrb.2014.06.008.
Jamilian, Hamidreza, et al. “Oral Carnitine Supplementation Influences Mental Health Parameters and Biomarkers of Oxidative Stress in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.” Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology, vol. 33, no. 6, June 2017, pp. 442–47. PubMed, https://doi.org/10.1080/09513590.2017.1290071.
Jamilian, Mehri, et al. “Metabolic Response to Selenium Supplementation in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.” Clinical Endocrinology, vol. 82, no. 6, June 2015, pp. 885–91. PubMed, https://doi.org/10.1111/cen.12699.
Khan, Muhammad Jaseem, et al. “Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives.” The Application of Clinical Genetics, vol. 12, Dec. 2019, pp. 249–60. PubMed Central, https://doi.org/10.2147/TACG.S200341.
Kim, Jin Ju, et al. “FSH Receptor Gene p. Thr307Ala and p. Asn680Ser Polymorphisms Are Associated with the Risk of Polycystic Ovary Syndrome.” Journal of Assisted Reproduction and Genetics, vol. 34, no. 8, Aug. 2017, pp. 1087–93. PubMed, https://doi.org/10.1007/s10815-017-0953-z.
Konieczna, Aleksandra, et al. “Serum Bisphenol A Concentrations Correlate with Serum Testosterone Levels in Women with Polycystic Ovary Syndrome.” Reproductive Toxicology (Elmsford, N.Y.), vol. 82, Dec. 2018, pp. 32–37. PubMed, https://doi.org/10.1016/j.reprotox.2018.09.006.
Laganà, Antonio Simone, et al. “Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols.” International Journal of Endocrinology, vol. 2016, 2016, p. 6306410. PubMed, https://doi.org/10.1155/2016/6306410.
Lerchbaum, E., et al. “Susceptibility Loci for Polycystic Ovary Syndrome on Chromosome 2p16.3, 2p21, and 9q33.3 in a Cohort of Caucasian Women.” Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 43, no. 11, Oct. 2011, pp. 743–47. PubMed, https://doi.org/10.1055/s-0031-1286279.
Li, Chao, et al. “Association of Rs10830963 and Rs10830962 SNPs in the Melatonin Receptor (MTNR1B) Gene among Han Chinese Women with Polycystic Ovary Syndrome.” Molecular Human Reproduction, vol. 17, no. 3, Mar. 2011, pp. 193–98. PubMed, https://doi.org/10.1093/molehr/gaq087.
Li, Meng-Fei, et al. “The Effect of Berberine on Polycystic Ovary Syndrome Patients with Insulin Resistance (PCOS-IR): A Meta-Analysis and Systematic Review.” Evidence-Based Complementary and Alternative Medicine : ECAM, vol. 2018, Nov. 2018, p. 2532935. PubMed Central, https://doi.org/10.1155/2018/2532935.
Li, Shang, et al. “Altered Circadian Clock as a Novel Therapeutic Target for Constant Darkness-Induced Insulin Resistance and Hyperandrogenism of Polycystic Ovary Syndrome.” Translational Research, vol. 219, May 2020, pp. 13–29. ScienceDirect, https://doi.org/10.1016/j.trsl.2020.02.003.
Liu, Zhengling, et al. “Effects of ADIPOQ Polymorphisms on PCOS Risk: A Meta-Analysis.” Reproductive Biology and Endocrinology : RB&E, vol. 16, Dec. 2018, p. 120. PubMed Central, https://doi.org/10.1186/s12958-018-0439-6.
Mahesh, Virendra B. “Hirsutism, Virilism, Polycystic Ovarian Disease, and the Steroid-Gonadotropin-Feedback System: A Career Retrospective.” American Journal of Physiology – Endocrinology and Metabolism, vol. 302, no. 1, Jan. 2012, pp. E4–18. PubMed Central, https://doi.org/10.1152/ajpendo.00488.2011.
Pau, Cindy T., et al. “Phenotype and Tissue Expression as a Function of Genetic Risk in Polycystic Ovary Syndrome.” PLoS ONE, vol. 12, no. 1, Jan. 2017, p. e0168870. PubMed Central, https://doi.org/10.1371/journal.pone.0168870.
Perelman, Dalia, et al. “Substituting Poly- and Mono-Unsaturated Fat for Dietary Carbohydrate Reduces Hyperinsulinemia in Women with Polycystic Ovary Syndrome.” Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology, vol. 33, no. 4, Apr. 2017, pp. 324–27. PubMed, https://doi.org/10.1080/09513590.2016.1259407.
“Polycystic Ovary Syndrome Support Groups Are Helpful.” PCOS Awareness Association, https://www.pcosaa.org/overview. Accessed 21 July 2022.
Qiu, S., et al. “Exercise Training Improved Insulin Sensitivity and Ovarian Morphology in Rats with Polycystic Ovary Syndrome.” Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 41, no. 12, Dec. 2009, pp. 880–85. PubMed, https://doi.org/10.1055/s-0029-1234119.
Ranjzad, Fariba, et al. “A Common Variant in the Adiponectin Gene and Polycystic Ovary Syndrome Risk.” Molecular Biology Reports, vol. 39, no. 3, Mar. 2012, pp. 2313–19. PubMed, https://doi.org/10.1007/s11033-011-0981-1.
Romitti, Mirian, et al. “Association between PCOS and Autoimmune Thyroid Disease: A Systematic Review and Meta-Analysis.” Endocrine Connections, vol. 7, no. 11, Oct. 2018, pp. 1158–67. PubMed, https://doi.org/10.1530/EC-18-0309.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. “Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS).” Human Reproduction (Oxford, England), vol. 19, no. 1, Jan. 2004, pp. 41–47. PubMed, https://doi.org/10.1093/humrep/deh098.
Samimi, Mansooreh, et al. “Oral Carnitine Supplementation Reduces Body Weight and Insulin Resistance in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.” Clinical Endocrinology, vol. 84, no. 6, June 2016, pp. 851–57. PubMed, https://doi.org/10.1111/cen.13003.
Shahebrahimi, Karoon, et al. “Comparison Clinical and Metabolic Effects of Metformin and Pioglitazone in Polycystic Ovary Syndrome.” Indian Journal of Endocrinology and Metabolism, vol. 20, no. 6, Dec. 2016, pp. 805–09. PubMed, https://doi.org/10.4103/2230-8210.192925.
Sohrevardi, Seyed Mojtaba, et al. “Evaluating the Effect of Insulin Sensitizers Metformin and Pioglitazone Alone and in Combination on Women with Polycystic Ovary Syndrome: An RCT.” International Journal of Reproductive Biomedicine, vol. 14, no. 12, Dec. 2016, pp. 743–54.
Spinedi, Eduardo, and Daniel P. Cardinali. “The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy.” International Journal of Endocrinology, vol. 2018, July 2018, p. e1349868. www.hindawi.com, https://doi.org/10.1155/2018/1349868.
staff, familydoctor org editorial. “Polycystic Ovary Syndrome – Symptoms.” Familydoctor.Org, https://familydoctor.org/condition/polycystic-ovary-syndrome/. Accessed 21 July 2022.
Tagliaferri, Valeria, et al. “Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study.” Reproductive Sciences (Thousand Oaks, Calif.), vol. 25, no. 2, Feb. 2018, pp. 269–75. PubMed, https://doi.org/10.1177/1933719117711262.
Vahedi, Mahjoob, et al. “Metabolic and Endocrine Effects of Bisphenol A Exposure in Market Seller Women with Polycystic Ovary Syndrome.” Environmental Science and Pollution Research International, vol. 23, no. 23, Dec. 2016, pp. 23546–50. PubMed, https://doi.org/10.1007/s11356-016-7573-5.
Valkenburg, O., et al. “Genetic Polymorphisms of GnRH and Gonadotrophic Hormone Receptors Affect the Phenotype of Polycystic Ovary Syndrome.” Human Reproduction (Oxford, England), vol. 24, no. 8, Aug. 2009, pp. 2014–22. PubMed, https://doi.org/10.1093/humrep/dep113.
Wei, Wei, et al. “A Clinical Study on the Short-Term Effect of Berberine in Comparison to Metformin on the Metabolic Characteristics of Women with Polycystic Ovary Syndrome.” European Journal of Endocrinology, vol. 166, no. 1, Jan. 2012, pp. 99–105. PubMed, https://doi.org/10.1530/EJE-11-0616.
Wickenheisser, Jessica K., et al. “Retinoids and Retinol Differentially Regulate Steroid Biosynthesis in Ovarian Theca Cells Isolated from Normal Cycling Women and Women with Polycystic Ovary Syndrome.” The Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, Aug. 2005, pp. 4858–65. PubMed, https://doi.org/10.1210/jc.2005-0330.
Wu, Chuyan, et al. “Exercise Activates the PI3K-AKT Signal Pathway by Decreasing the Expression of 5α-Reductase Type 1 in PCOS Rats.” Scientific Reports, vol. 8, no. 1, May 2018, p. 7982. PubMed, https://doi.org/10.1038/s41598-018-26210-0.
Wu, Yuanyuan, et al. “Metformin and Pioglitazone Combination Therapy Ameliorate Polycystic Ovary Syndrome through AMPK/PI3K/JNK Pathway.” Experimental and Therapeutic Medicine, vol. 15, no. 2, Feb. 2018, pp. 2120–27. PubMed, https://doi.org/10.3892/etm.2017.5650.
Zou, Ju, et al. “Association of Luteinizing Hormone/Choriogonadotropin Receptor Gene Polymorphisms with Polycystic Ovary Syndrome Risk: A Meta-Analysis.” Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology, vol. 35, no. 1, Jan. 2019, pp. 81–85. PubMed, https://doi.org/10.1080/09513590.2018.1498834.
Updated May 15, 2020